Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 6/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16126021 | 0.75 | GRIN1 (0.34) | GRIN1GRIN2AGRIN2DGRIN2CGRIN2B | |
| SCHEMBL17282080 | 0.75 | GRIN1 (0.34) | GRIN1GRIN2AGRIN2DGRIN2CGRIN2B | |
| SCHEMBL26465300 | 0.73 | — | — | |
| SCHEMBL27371291 | 0.73 | GRIN1 (0.33) | GRIN1GRIN2AGRIN2DGRIN2CGRIN2B | |
| SCHEMBL27936381 | 0.72 | — | — | |
| SCHEMBL25083630 | 0.72 | — | — | |
| SCHEMBL100229 | 0.71 | — | — | |
| SCHEMBL20768162 | 0.70 | GRIN1 (0.32) | GRIN1GRIN2AGRIN2DGRIN2CGRIN2B | |
| SCHEMBL19034555 | 0.70 | GRIN1 (0.32) | GRIN1GRIN2AGRIN2DGRIN2CGRIN2B | |
| SCHEMBL12557935 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3928779-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | Chugai Seiyaku Kabushiki Kaisha (JP) | 2021-12-29 | — | — | EP | disclosed |
| US-11022592-B2 | Chemical self-doping of one-dimensional organic nanomaterials for high conductivity application in chemiresistive sensing gas or vapor | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-20170160252-A1 | CHEMICAL SELF-DOPING OF ONE-DIMENSIONAL ORGANIC NANOMATERIALS FOR HIGH CONDUCTIVITY APPLICATION IN CHEMIRSISTIVE SENSING GAS OR VAPOR | UNIVERSITY OF UTAH | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170160252-A1 | CHEMICAL SELF-DOPING OF ONE-DIMENSIONAL ORGANIC NANOMATERIALS FOR HIGH CONDUCTIVITY APPLICATION IN CHEMIRSISTIVE SENSING GAS OR VAPOR | DRD1, DRD4, DNER | GRIN1 1874/4885GRIN2A 2074/4885GRIN2D 319/4885 |
| US-11022592-B2 | Chemical self-doping of one-dimensional organic nanomaterials for high conductivity application in chemiresistive sensing gas or vapor | DRD1, DRD2, DNER | GRIN1 1561/4885GRIN2A 1727/4885GRIN2D 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.